The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity
Open accessAbstract
Conventional type 1 dendritic cells (cDC1)1 are thought to perform antigen cross-presentation, which is required to prime CD8+ T cells 2,3, whereas cDC2 are specialized for priming CD4+ T cells 4,5. CD4+ T cells are also considered to help CD8+ T cell responses through a variety of mechanisms 6-11, including a process whereby CD4+ T cells 'license' cDC1 for CD8+ T cell priming 12. However, this model has not been directly tested in vivo or in the setting of help-dependent tumour rejection. Here we generated an Xcr1 Cre mouse strain to evaluate the cellular interactions that mediate tumour rejection in a model requiring CD4+ and CD8+ T cells. As expected, tumour rejection required cDC1 and CD8+ T cell priming required the expression of major histocompatibility class I molecules by cDC1. Unexpectedly, early priming of CD4+ T cells against tumour-derived antigens also required cDC1, and this was not simply because they transport antigens to lymph nodes for processing by cDC2, as selective deletion of major histocompatibility class II molecules in cDC1 also prevented early CD4+ T cell priming. Furthermore, deletion of either major histocompatibility class II or CD40 in cDC1 impaired tumour rejection, consistent with a role for cognate CD4+ T cell interactions and CD40 signalling in cDC1 licensing. Finally, CD40 signalling in cDC1 was critical not only for CD8+ T cell priming, but also for initial CD4+ T cell activation. Thus, in the setting of tumour-derived antigens, cDC1 function as an autonomous platform capable of antigen processing and priming for both CD4+ and CD8+ T cells and of the direct orchestration of their cross-talk that is required for optimal anti-tumour immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“cDC1 are critical for antigen cross-presentation required to prime CD8+ T cells for optimal anti-tumor immunity and priming of CD4+ T cells at early stages, partly because cDC1 provides antigen transportation to lymph nodes for processing by cDC2 (36).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [36]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CD40 signaling in cDC1 is required for tumor rejection by playing a key role in augmenting the proliferation of antigen-specific CD8+ T cells (36).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus
Srinivas, S., Watanabe, T., Lin, C.-S., William, C. M., Tanabe, Y., Jessell, T. M., & Costantini, F. (2001) · BMC Developmental Biology · doi:10.1186/1471-213x-1-4 · Cited by 3,121
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Ridge, J. P., Rosa, F. D., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,360
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Bennett, S. R. M., Carbone, F., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,091
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny
Guilliams, M., Ginhoux, F., Jakubzick, C., Naik, S. H., Onai, N., Schraml, B. U., Segura, É., Tussiwand, R., & Yona, S. (2014) · Nature reviews. Immunology · doi:10.1038/nri3712 · Cited by 1,923
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,454
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,285
Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help
Sun, J. C., & Bevan, M. J. (2003) · Science · doi:10.1126/science.1083317 · Cited by 1,213
Cited by
Sorted by citations
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,570
Zhang, Y., Chen, H., Mo, H., Hu, X., Gao, R., Zhao, Y., Liu, B., Niu, L., Sun, X., Yu, X., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.010 · Cited by 783
Cabeza-Cabrerizo, M., Cardoso, A., Minutti, C. M., Pereira da Costa, M., & Reis e Sousa, C. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-061020-053707 · Cited by 757
Dendritic cell subsets in cancer immunity and tumor antigen sensing
Prete, A. D., Salvi, V., Soriani, A., Laffranchi, M., Sozio, F., Bosisio, D., & Sozzani, S. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-00990-6 · Cited by 682
Speiser, D. E., Chijioke, O., Schaeuble, K., & Münz, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00521-2 · Cited by 511
Cui, C., Wang, J., Fagerberg, E., Chen, P.-M., Connolly, K. A., Damo, M., Cheung, J. F., Mao, T., Askari, A. S., Chen, S., et al. (2020) · Cell · doi:10.1016/j.cell.2021.11.007 · Cited by 493
CD8+ T cells in the cancer-immunity cycle
Giles, J. R., Globig, A.-M., Kaech, S. M., & Wherry, E. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.005 · Cited by 491
Magen, A., Hamon, P., Fiaschi, N., Soong, B. Y., Park, M. D., Mattiuz, R., Humblin, E., Troncoso, L., D’souza, D., Dawson, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02345-0 · Cited by 429
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer
Huang, L., Rong, Y., Tang, X., Yi, K., Qi, P., Hou, J., Liu, W., He, Y. Z., Gao, X., Yuan, C., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01515-x · Cited by 416
Dendritic cells as orchestrators of anticancer immunity and immunotherapy
Heras‐Murillo, I., Adán‐Barrientos, I., Galán, M. Á., Wculek, S. K., & Sancho, D. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00859-1 · Cited by 418
Cancer vaccines: Building a bridge over troubled waters
Sellars, M., Wu, C. J., & Fritsch, E. F. (2022) · Cell · doi:10.1016/j.cell.2022.06.035 · Cited by 330
Dendritic cells as shepherds of T cell immunity in cancer
Pittet, M. J., Pilato, M. D., Garris, C., & Mempel, T. R. (2023) · Immunity · doi:10.1016/j.immuni.2023.08.014 · Cited by 330
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
Basu, A. B., Ramamoorthi, G., Albert, G. K., Gallen, C., Beyer, A., Snyder, C., Koski, G. K., Disis, M. L., Czerniecki, B. J., & Kodumudi, K. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669474 · Cited by 329
CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours
Kruse, B., Buzzai, A. C., Shridhar, N., Braun, A. D., Gellert, S., Knauth, K., Poźniak, J., Peters, J., Dittmann, P., Mengoni, M., et al. (2023) · Nature · doi:10.1038/s41586-023-06199-x · Cited by 343
SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity
Guo, C., You, Z., Shi, H., Sun, Y., Du, X., Palacios, G. F., Guy, C. S., Yuan, S., Chapman, N. M., Lim, S. A., et al. (2023) · Nature · doi:10.1038/s41586-023-06299-8 · Cited by 325
The role of dendritic cells in cancer and anti-tumor immunity
Marciscano, A. E. E., & Anandasabapathy, N. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101481 · Cited by 314
Cancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 297
Dendritic cells in cancer immunology
Murphy, T. L., & MURPHY, K. M. M. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00741-5 · Cited by 281
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
Pei, L., Liu, Y., Liu, L., Gao, S., Gao, X., Feng, Y., Sun, Z., Zhang, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01731-z · Cited by 270
Human dendritic cells in cancer
Kvedaraite, E., & Ginhoux, F. (2022) · Science Immunology · doi:10.1126/sciimmunol.abm9409 · Cited by 272
Abdominal Aortic Aneurysm: Roles of Inflammatory Cells
Yuan, Z., Lü, Y., Wei, J., Wu, J., Yang, J., & Cai, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609161 · Cited by 232
Exploiting innate immunity for cancer immunotherapy
Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 250
Targeting innate immune pathways for cancer immunotherapy
Cao, L. L., & Kagan, J. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.07.018 · Cited by 234
Stem-like exhausted and memory CD8+ T cells in cancer
Gebhardt, T., Park, S. L., & Parish, I. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00615-0 · Cited by 223
Designing Cancer Immunotherapies That Engage T Cells and NK Cells
Kyrysyuk, O., & Wucherpfennig, K. W. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-044122 · Cited by 220
Meiser, P., Knolle, M. A., Hirschberger, A., de Almeida, G. P., Bayerl, F., Lacher, S. B., Pedde, A., Flommersfeld, S., Hönninger, J., Stark, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.008 · Cited by 208
Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts
Kerdidani, D., Aerakis, E., Verrou, K., Angelidis, I., Douka, K., Maniou, M.-A., Stamoulis, P., Goudevenou, K., Prados, A., Tzaferis, C., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210815 · Cited by 209
Cohen, M., Giladi, A., Barboy, O., Hamon, P., Li, B., Zada, M., Gurevich‐Shapiro, A., Beccaría, C. G., David, E., Maier, B. B., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00338-5 · Cited by 204
Lactate limits CNS autoimmunity by stabilizing HIF-1α in dendritic cells
Sanmarco, L. M., Rone, J. M., Polonio, C. M., Lahore, G. F., Giovannoni, F., Ferrara, K., Gutiérrez‐Vázquez, C., Li, N., Sokolovska, A., Plasencia, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06409-6 · Cited by 206
Duraiswamy, J., Turrini, R., Minasyan, A., Barras, D., Crespo, I., Grimm, A. J., Casado, J., Genolet, R., Benedetti, F., Wicky, A. M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.008 · Cited by 191
Multi-stage mechanisms of tumor metastasis and therapeutic strategies
Liu, Z., Chen, J., Ren, Y., Liu, S., Ba, Y., Zuo, A., Luo, P., Cheng, Q., Xu, H., & Han, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01955-5 · Cited by 208
The tumor microenvironment’s role in the response to immune checkpoint blockade
Aliazis, K., Christofides, A., Shah, R., Yeo, Y. Y., Jiang, S., Charest, A., & Boussiotis, V. A. (2025) · Nature Cancer · doi:10.1038/s43018-025-00986-3 · Cited by 208
Dendritic cell maturation in cancer
Moon, C. Y., Belabed, M., Park, M. D., Mattiuz, R., Puleston, D. J., & Mérad, M. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00787-3 · Cited by 189
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Kim, S. I., Cassella, C. R., & Byrne, K. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.629722 · Cited by 174
Zhivaki, D., Borriello, F., Chow, O. A., Doran, B. A., Fleming, I., Theisen, D. J., Pallis, P., Shalek, A. K., Sokol, C. L., Zanoni, I., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108381 · Cited by 168
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance
Zavitsanou, A., Pillai, R., Yuan, H., Wu, W., Bartnicki, E., Karakousi, T. R., Rajalingam, S., Herrera, A. M., Karatza, A., Rashidfarrokhi, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113295 · Cited by 157
In vivo dendritic cell reprogramming for cancer immunotherapy
Ascic, E., Åkerström, F., Nair, M. S., Rosa, A., Kurochkin, I., Zimmermannová, O., Catena, X., Rotankova, N., Veser, C., Rudnik, M., et al. (2024) · Science · doi:10.1126/science.adn9083 · Cited by 148
Challenges in neoantigen-directed therapeutics
Lybaert, L., Lefever, S., Fant, B., Smits, E., Geest, B. G. D., Breckpot, K., Dirix, L. Y., Feldman, S. A., Criekinge, W. V., Thielemans, K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.013 · Cited by 147
Control of adaptive immunity by pattern recognition receptors
Carroll, S. L., Pasare, C., & Barton, G. M. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.014 · Cited by 155
A vaccine targeting resistant tumours by dual T cell plus NK cell attack
Badrinath, S., Dellacherie, M. O., Li, A. W., Zheng, S.-W., Zhang, X., Sobral, M. C., Pyrdol, J. W., Smith, K. L., Lu, Y., Haag, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04772-4 · Cited by 137
STING licensing of type I dendritic cells potentiates antitumor immunity
Wang, J., Li, S., Wang, M., Wang, X., Chen, S., Sun, Z., Ren, X., Huang, G., Sumer, B. D., Yan, N., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adj3945 · Cited by 146
Zhang, Y., Chen, H., Mo, H., Zhao, N., Sun, X., Liu, B., Gao, R., Xu, B., Zhang, Z., Liu, Z., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.007 · Cited by 153
Radiation therapy-induced remodeling of the tumor immune microenvironment
Charpentier, M., Spada, S., Nest, S. J. V., & Demaria, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.003 · Cited by 146
Oba, T., Long, M. D., Keler, T., Marsh, H. C., Minderman, H., Abrams, S. I., Liu, S., & Ito, F. (2020) · Nature Communications · doi:10.1038/s41467-020-19192-z · Cited by 140
The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy
Cueto, F. J., & Sancho, D. (2021) · Cancers · doi:10.3390/cancers13071525 · Cited by 137
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Wang, Y., Johnson, K. C. C., Gatti-Mays, M. E., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01335-y · Cited by 136
CD4+ T cells in antitumor immunity
Montauti, E. I., Oh, D. Y., & Fong, L. H. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.07.009 · Cited by 148
Cross-priming in cancer immunology and immunotherapy
Luri‐Rey, C., Teijeira, Á., Wculek, S. K., de Andrea, C. E., Herrero, C., López‐Janeiro, Á., Rodriguez-Ruiz, M. E., Heras‐Murillo, I., Aggelakopoulou, M., Berraondo, P., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00785-5 · Cited by 147
NF-κB–dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity
Ghislat, G., Cheema, A. S., Baudoin, E., Verthuy, C., Ballester, P. J., Crozat, K., Attaf, N., Dong, C., Milpied, P., MALISSEN, B., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg3570 · Cited by 131
Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment
Wang, Q., Yu, Y., Zhuang, J., Liu, R., & Sun, C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02380-0 · Cited by 142
The tumor-draining lymph node as a reservoir for systemic immune surveillance
Delclaux, I., Ventre, K. S., Jones, D., & Lund, A. W. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.09.006 · Cited by 138
Gargaro, M., Scalisi, G., Manni, G., Briseño, C. G., Bagadia, P., Durai, V., Theisen, D. J., Kim, S. K., Castelli, M., Xu, C. A., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.013 · Cited by 130
Kilian, M., Sheinin, R., Tan, C. L., Friedrich, M., Krämer, C., Kaminitz, A., Sanghvi, K., Lindner, K. A. M., Chih, Y., Cichon, F., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.007 · Cited by 121
CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses
He, M., Roussak, K., Ma, F., Borcherding, N. C., Garin, V., White, J. M., Schutt, C. R., Jensen, T. I., Zhao, Y., Iberg, C. A., et al. (2023) · Science · doi:10.1126/science.abg2752 · Cited by 121
Wang, Y., Zhong, X., He, X., Hu, Z., Huang, H., Chen, J., Chen, K., Zhao, S., Wei, P., & Li, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02729-7 · Cited by 131
Dähling, S., Mansilla, A. M., Knöpper, K., Grafen, A., Utzschneider, D. T., Ugur, M., Whitney, P. G., Bachem, A., Arampatzi, P., Imdahl, F., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.006 · Cited by 109
CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
Bullock, T. N. J. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00734-4 · Cited by 117
cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors
Li, G., Zhao, X., Zheng, Z., Zhang, H., Wu, Y., Shen, Y., & Chen, Q. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05191-6 · Cited by 112
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy
Sultan, H., Takeuchi, Y., Ward, J. P., Sharma, N., Liu, T., Sukhov, V., Firulyova, M. M., Song, Y., Ameh, S., Brioschi, S., et al. (2024) · Nature · doi:10.1038/s41586-024-07752-y · Cited by 105
Liu, W., Hu, H., Shao, Z., Lv, X., Zhang, Z., Deng, X., Song, Q., Han, Y. N., Guo, T., Xiong, L., et al. (2023) · Bone Research · doi:10.1038/s41413-022-00237-6 · Cited by 105
Decoding immunogenic cell death from a dendritic cell perspective
Janssens, S., Rennen, S., & Agostinis, P. (2023) · Immunological Reviews · doi:10.1111/imr.13301 · Cited by 106
CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment
Lei, X., Khatri, I., de Wit, T., de Rink, I., Nieuwland, M., Kerkhoven, R. M., van Eenennaam, H., Sun, C., Garg, A. D., Borst, J. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35615-5 · Cited by 99
Type I IFN activating type I dendritic cells for antitumor immunity
Liang, Y., Hannan, R., & Fu, Y.-X. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2564 · Cited by 91
Xia, Y., Sándor, K., Pai, J. A., Dániel, B., Raju, S., Wu, R., Hsiung, S., Qi, Y., Tenzin, Y., Okamoto, M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.003 · Cited by 91
pDC-like cells are pre-DC2 and require KLF4 to control homeostatic CD4 T cells
Rodrigues, P. F., Kouklas, A., Cvijetic, G., Bouladoux, N. J., Mitrovic, M., Desai, J. V., Lima-Junior, D. S., Lionakis, M. S., Belkaid, Y., Ivánek, R., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add4132 · Cited by 87
The Role of Plasmacytoid Dendritic Cells in Cancers
Zhou, B., Lawrence, T., & Liang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.749190 · Cited by 90
Glioblastoma vaccines: past, present, and opportunities
Xiong, Z., Raphael, I., Olin, M. R., Okada, H., Li, X., & Kohanbash, G. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2023.104963 · Cited by 96
Zhang, X., Goedegebuure, S. P., Chen, M. Y., Mishra, R., Zhang, F., Yu, Y. Y., Singhal, K., Li, L., Gao, F., Myers, N. B., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01388-3 · Cited by 89
Dendritic cell functions in the inductive and effector sites of intestinal immunity
Luciani, C., Hager, F. T., Cerovic, V., & Lelouard, H. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00448-w · Cited by 99
Striking a balance: new perspectives on homeostatic dendritic cell maturation
Bosteels, V., & Janssens, S. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01079-5 · Cited by 90
Architects of immunity: How dendritic cells shape CD8 + T cell fate in cancer
Bhandarkar, V., Dinter, T., & Spranger, S. (2025) · Science Immunology · doi:10.1126/sciimmunol.adf4726 · Cited by 88
Garris, C., Wong, J. L., Ravetch, J. V., & Knorr, D. A. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1346 · Cited by 79
Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape
Sharma, P., Zhang, X., Ly, K., Kim, J. H., Wan, Q., Kim, J., Lou, M., Kain, L., Teyton, L., & Winau, F. (2024) · Science · doi:10.1126/science.adg1955 · Cited by 85
Sittplangkoon, C., Alameh, M.-G., Weissman, D., Lin, P. J. C., Tam, Y. K., Prompetchara, E., & Palaga, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983000 · Cited by 79
“CD40 signaling in cDC1 is required for tumor rejection by playing a key role in augmenting the proliferation of antigen-specific CD8 T cells (36).”
BackgroundAntigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy
Moussion, C., & Delamarre, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101848 · Cited by 82
Brightman, S. E., Becker, A., Thota, R. R., Naradikian, M. S., Chihab, L. Y., Zavala, K. S., Premlal, A. L. R., Griswold, R. Q., Dolina, J. S., Cohen, E. E. W., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01543-9 · Cited by 79
Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
Salomon, R., & Dahan, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940674 · Cited by 76
Mechanisms of CD40-dependent cDC1 licensing beyond costimulation
Wu, R., Ohara, R. A., Jo, S., Liu, T., Ferris, S. T., Ou, F., Kim, S. K., Theisen, D. J., Anderson, D. A., Wong, B. W., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01324-w · Cited by 75
Lipid metabolism in dendritic cell biology
You, Z., & Chi, H. (2023) · Immunological Reviews · doi:10.1111/imr.13215 · Cited by 81
CD4 + T cell immunity against cutaneous melanoma encompasses multifaceted MHC II–dependent responses
Bawden, E., Wagner, T., Schröder, J., Effern, M., Hinze, D., Newland, L., Attrill, G. H., Lee, A. R., Engel, S., Freestone, D., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi9517 · Cited by 76
Humblin, É., Korpas, I., Lu, J., Filipescu, D., van der Heide, V., Goldstein, S., Vaidya, A. B., Schanoski, A. S., Casati, B., Selvan, M. E., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg0878 · Cited by 72
Lymphatic vessels in the age of cancer immunotherapy
Karakousi, T. R., Mudianto, T., & Lund, A. W. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00681-y · Cited by 79
Zhang, B., Liu, J., Mo, Y., Zhang, K., Huang, B., & Shang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1476904 · Cited by 84
An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses
Aunins, E., Phan, A. T., Alameh, M., Dwivedi, G., Cruz-Morales, E., Christian, D. A., Tam, Y. K., Bunkofske, M. E., Zabala-Peñafiel, A., O’Dea, K. M., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.ads1328 · Cited by 75
Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design
Clemente, B., Denis, M., Silveira, C. P., Schiavetti, F., Brazzoli, M., & Stranges, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294929 · Cited by 71
Ishihara, M., Kitano, S., Kageyama, S., Miyahara, Y., Yamamoto, N., Kato, H., Mishima, H., Hattori, H., Funakoshi, T., Kojima, T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003811 · Cited by 72
Dolina, J. S., Lee, J., Brightman, S. E., McArdle, S., Hall, S. M., Thota, R. R., Zavala, K. S., Lanka, M., Premlal, A. L. R., Greenbaum, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164258 · Cited by 68
DCision-making in tumors governs T cell anti-tumor immunity
Alfei, F., Ho, P., & Lo, W. (2021) · Oncogene · doi:10.1038/s41388-021-01946-8 · Cited by 68
Lei, X., de Groot, D., Welters, M. J. P., de Wit, T., Schrama, E., van Eenennaam, H., Santegoets, S. J. A. M., Oosenbrug, T., van der Veen, A. G., Vos, J. L., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01133-1 · Cited by 71
The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets
Kim, C. W., Kim, K., & Lee, H. K. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.224 · Cited by 65
Topchyan, P., Lin, S., & Cui, W. (2023) · Immune Network · doi:10.4110/in.2023.23.e41 · Cited by 73
Dendritic Cells in Shaping Anti-Tumor T Cell Response
Mazzoccoli, L., & Liu, B. (2024) · Cancers · doi:10.3390/cancers16122211 · Cited by 71
Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer
Mahadevan, K. K., Dyevoich, A. M., Chen, Y., Li, B., Sugimoto, H., Sockwell, A. M., McAndrews, K. M., Sthanam, L. K., Wang, H., Shalapour, S., et al. (2024) · Science · doi:10.1126/science.adh4567 · Cited by 71
Type 2 dendritic cells mediate control of cytotoxic T cell resistant tumors
Iwanowycz, S., Ngoi, S. M., Li, Y., Hill, M., Koivisto, C. S., Parrish, M., Guo, B., Li, Z., & Liu, B. (2021) · JCI Insight · doi:10.1172/jci.insight.145885 · Cited by 67
Lança, T., Ungerbäck, J., Silva, C. D., Joeris, T., Ahmadi, F., Vandamme, J., Svensson, M., Mowat, A. M., Kotarsky, K., Sigvardsson, M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.06.006 · Cited by 64
Kraja, F., Jurišić, V., Hromić-Jahjefendić, A., Rossopoulou, N., Κάτσιλα, Θ., Martinović, K. M., Rivas, J. D. L., Diaconu, C. C., & Szöőr, Á. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1601773 · Cited by 71
Defining and using immune archetypes to classify and treat cancer
Combes, A. J., Samad, B., & Krummel, M. F. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00578-2 · Cited by 61
cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1
Ferris, S. T., Ohara, R. A., Ou, F., Wu, R., Huang, X., Kim, S. K., Chen, J., Liu, T., Schreiber, R. D., Murphy, T. L., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0865 · Cited by 61
Backlund, C. M., Holden, R. L., Moynihan, K. D., Garafola, D., Farquhar, C., Mehta, N. K., Maiorino, L., Pham, S., Iorgulescu, J. B., Reardon, D. A., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204078119 · Cited by 61
Antigen-presenting cells as specialized drivers of intestinal T cell functions
Kedmi, R., & Littman, D. R. (2024) · Immunity · doi:10.1016/j.immuni.2024.09.011 · Cited by 64
Metadata
- Authors
- Ferris, S. T., Durai, V., Wu, R., Theisen, D. J., Ward, J. P., Bern, M. D., Davidson, J. T., Bagadia, P., Liu, T., Briseño, C. G., Li, L., Gillanders, W. E., Wu, G. F., Yokoyama, W. M., Murphy, T. L., Schreiber, R. D., & Murphy, K. M.
- Affiliations
- Washington University in St. Louis (US)
- University of California, San Francisco (US)
- Barnes-Jewish Hospital (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Murphy, Kenneth M.
- ORCID
- Venue
- Nature
- Published
- 2020-08-12
- Volume
- 584
- Issue
- 7822
- Pages
- 624-629
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7469755
- OpenAlex
- W3048641542
- Cited by
- 611
- References
- 50
- Citations by year
- 2026: 112 · 2025: 105 · 2024: 112 · 2023: 127 · 2022: 76 · 2021: 67 · 2020: 12
- FWCI
- 24.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (UL1TR000448, UL1TR002345)
- National Cancer Institute (T32CA009573, R01CA190700, T32CA009621, R01CA248919, P30CA091842)
- National Institute of Allergy and Infectious Diseases (R01AI150297, R01AI129545, T32AI007163, R01AI162643)
- National Institute of Diabetes and Digestive and Kidney Diseases (F30DK108498, F30DK112466)
- National Institute of Neurological Disorders and Stroke (R01NS106289)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR073752)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- conventional type 1 dendritic cells, cDC1, CD4+ T cell priming, CD8+ T cell priming, MHC class II, MHC class I, cross-presentation, tumor rejection, antitumor immunity
- MeSH terms
- Animals, Histocompatibility Antigens Class II, Dendritic Cells, Female, Neoplasms, Signal Transduction, CD4-Positive T-Lymphocytes, Antigen Presentation, CD8-Positive T-Lymphocytes, CD40 Antigens, Cross-Priming, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
